ArticleBMC gastroenterology2026
ACE inhibitor-induced isolated intestinal angioedema mimicking functional bowel disorder: a case report.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiotensin-converting enzyme (ACE) inhibitor-induced intestinal angioedema is a rare but clinically significant adverse drug reaction. Isolated visceral involvement, occurring without the cutaneous, oropharyngeal, or laryngeal manifestations classically associated with ACE inhibitor angioedema, is particularly under-recognised and is repeatedly mistaken for common gastrointestinal disorders. Most reported cases describe symptom onset within hours to days of initiation; cases with subacute onset over several weeks-mimicking a functional bowel disorder-are far less well characterised. CASE PRESENTATION: A 54-year-old Indian woman with essential hypertension developed recurrent diffuse abdominal pain, intermittent loose stools, and nausea approximately six weeks after starting enalapril 10 mg once daily. She had no urticaria, pruritus, facial swelling, or oropharyngeal involvement. Vital signs were stable, and abdominal examination demonstrated mild diffuse tenderness without peritoneal signs. She was managed at peripheral facilities for presumed acute gastroenteritis and subsequently irritable bowel syndrome, with no meaningful response to standard therapy. Comprehensive evaluation excluded infectious, inflammatory, autoimmune, and hereditary causes; serum complement C4 was normal. The clinical diagnosis of ACE inhibitor-induced isolated intestinal angioedema was made on the basis of (i) angioedema-type presentation in the absence of urticaria or pruritus, (ii) temporal association with enalapril, (iii) exclusion of alternative aetiologies, and (iv) complete resolution following drug withdrawal. Causality was assessed as "probable" by the Naranjo Adverse Drug Reaction Probability Scale (score 7) and by the WHO-UMC criteria. After a structured wash-out, the patient was transitioned to losartan, with sustained blood pressure control and no recurrence over three months of follow-up.
conclusionsACE inhibitor-induced angioedema can present as isolated intestinal involvement and may evolve over weeks rather than hours, closely mimicking a functional bowel disorder. A meticulous medication history, formal causality assessment, and an empirical drug-withdrawal trial should be considered in any patient with unexplained, treatment-refractory gastrointestinal symptoms taking an ACE inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.